Tag Archives: Revlimid

What’s wrong with Celgene as shares get clobbered? Nothing, actually.

The News: Celgene Corp. (Summit NJ) plummeted 20% Thursday (October 26, 2017) to $99.99 after releasing third-quarter earnings. And it wasn’t so much third-quarter revenue, which was up 10% year over year,… Read more »

Healthcare stocks primed for comeback in 2017? Here are Steve’s top picks

The population of the world, and the US and developed nations in particular, is growing and getting older, while the costs of keeping people healthy and living longer are exploding…. Read more »